NCT05852769View on ClinicalTrials.gov

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

August 24, 2023

Study Completion Date

August 24, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986196

Specified dose on specified days

DRUG

Caffeine

Specified dose on specified days

DRUG

Montelukast

Specified dose on specified days

DRUG

Flurbiprofen

Specified dose on specified days

DRUG

Omeprazole

Specified dose on specified days

DRUG

Midazolam

Specified dose on specified days

DRUG

Digoxin

Specified dose on specified days

DRUG

Pravastatin

Specified dose on specified days

Trial Locations (1)

84124

ICON plc, Millcreek

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY